Market Overview

Afrezza Feedback 'Largely Positive' For MannKind, Jefferies Says

Related MNKD
Benzinga Pro's 5 Stocks To Watch Today
30 Biggest Movers From Friday
Your Daily Pharma Scoop: Takeda Acquisitions, Concert Trial Update, Sangamo Offering (Seeking Alpha)
Related SNY
The Week Ahead In Biotech: PDUFA Dates, IPOs And More
Alnylam's President Talks Strategy To Become A Top Biotech Company, 'Developing An Entirely New Class Of Medicine'
We Believe Janssen Has Separated From Geron. Just Awaiting Divorce Papers (Seeking Alpha)

In a report published Tuesday, Jefferies analyst Shaunak Deepak maintained a Buy rating on MannKind Corporation (NASDAQ: MNKD), with a price target of $9, following positive physician feedback on Afrezza at the American Diabetes Association (ADA) meeting.

"At the ADA meeting we spoke to 20 U.S. physicians who were familiar with Afrezza and found that while only six had prescribed the drug to date, only one of physicians was fundamentally concerned about prescribing it. The one physician who expressed caution about prescribing Afrezza said that he remained worried about delivery of insulin, a hormone, into the lung," analyst Shaunak Deepak said.

There were two pediatric endocrinologists who had decided against prescribing the drug until it received FDA approval for use in children. Both expressed optimism, however, regarding the eventual opportunity. In fact, one of them claimed that he would take Afrezza himself if he were diabetic.

In the report Jefferies noted, "Three physicians we spoke to worked for the VA/DOD and each expressed concerns with their ability get access to Afrezza, with one hoping for a broad government contract and another asserting it would never be put on formulary. Five physicians cited Afrezza's cost or the need for prior authorization as a primary reason for not yet prescribing the drug to their patients."

Three physicians indicated their hesitation to use Afrezza until they had identified "the ideal patient in need of insulin intensification," Deepak stated, while adding that the physicians' openness to prescribe Afrezza was a positive that could be leveraged with MannKind and Sanofi SA (ADR) (NYSE: SNY) increasing their efforts towards dialogues with payors and the commencement of direct-to-consumer ads in early 3Q.

Latest Ratings for MNKD

Mar 2018Maxim GroupDowngradesHoldSell
Nov 2017Maxim GroupDowngradesBuyHold
Oct 2017H.C. WainwrightInitiates Coverage OnBuy

View More Analyst Ratings for MNKD
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Reiteration Analyst Ratings


Related Articles (MNKD + SNY)

View Comments and Join the Discussion!